Since AFSP began in 1987, encouraging and supporting scientific research on suicide causation, prevention and treatment has been at the heart of the Foundation's mission. Our research grants program seeks to:
Encourage established investigators to undertake innovative approaches and explore new directions in suicide research;
Encourage talented new investigators to enter the field of suicide research through grants that provide training support and mentoring;
Provide seed money for pilot projects that show promise in opening up new areas of suicide research.
AFSP research grants support the work of investigators from all disciplines that contribute to our understanding of suicide and suicide prevention. Since 2000, AFSP has given grant support totaling over $10 million to scientists throughout the country and abroad for studies on neurobiological, genetic, epidemiological, clinical, psychological and sociological aspects of suicide. Since 2001, more than 95 percent of AFSP grantees have received further funding from public and private sources to continue their research. This shows that AFSP-funded research is making an impact, and is attracting young investigators to the field.
The National Institute of Mental Health (NIMH) announces an administrative supplement program to provide funds to research projects to support advanced research experiences of exceptional individuals holding the M.D./Ph.D. degree early in their research careers. The goal of this program is to provide opportunities for M.D./Ph.D.-trained individuals to continue to conduct research and to enhance their research skill set while completing clinical training, i.e., during the years of residency and clinical fellowship, and to contribute to the progress of the research grant. Support through this administrative supplement program is expected to enhance the scientific and professional development of the participating individuals, speed their transition to research independence as physician-scientists, and contribute to scientific knowledge that advances the mission of the NIMH.
The NCATS Pharmaceutical Collection (NPC), also known as the NIH
Chemical Genomics Center (NCGC) Pharmaceutical Collection, is a
comprehensive, publicly accessible collection of approved and
investigational drugs for high-throughput screening that provides a
valuable resource for both validating new models of disease and
better understanding the molecular basis of disease pathology and
intervention. The NPC already has generated several useful probes for
studying a diverse cross section of biology, including novel targets
and pathways. NCATS provides access to its set of approved drugs and
bioactives through the Therapeutics for Rare and Neglected Diseases
(TRND) program and as part of the compound collection for the Tox21
Initiative, a collaborative effort for toxicity screening among
several government agencies including the U.S. Environmental
Protection Agency (EPA), National Toxicology Program (NTP), and U.S.
Food and Drug Administration (FDA). Researchers who are interested in
NCATS' Therapeutics Discovery funding must submit a pre-application
in response to the NIH Funding Opportunity Announcement at
14, 2012. Applicants must include details about how they would
explore specific hypotheses related to one of the compounds that
might be useful in a specific disease area. The pre-applications will
undergo review by external experts, and while no funding will be
provided at this stage, successful applicants will be notified to
submit a full application for fiscal year 2013 funding.
For more information, visit http://www.nih.gov/news/health/jun2012/ncats-12.htm